 Zacks Investment Research downgraded shares of 89bio NASDAQ:ETNB from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports. According to Zacks, 89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. ... 